MeCo Diagnostics is a venture-backed startup developing predictive biomarkers for breast cancer and prostate cancer that harness a low-toxicity, generic-emergent, FDA-approved drug to prevent metastasis. Our team has 60+ years of leadership experience commercializing laboratory-developed tests/in vitro diagnostics, along with a stellar publication record. We will seek revenue sharing with an established clinical genomics services provider.